Therefore, given the lack of effective therapeutic strategies against KRAS-mutated cancers, it might be of interest to test the capacity of afatinib alone or combined with other drugs to inhibit the growth of EGFR/KRAS co-mutated NSCLC in human patients. Here, KRAS is linked to cancer.